It's not often that a pathologist gets to make a diagnosis that works for the patient by preventing treatment from occurring. But thanks to a Johns Hopkins Medicine doctor and his newly reported ...

CLD-201, an allogeneic adipose stem-cell loaded oncolytic virus, received FDA fast track designation for soft tissue sarcoma treatment. Fast track designation expedites drug development and review for ...

- Company Initiating Planning of Phase 2 Trial of Elraglusib in Children, Adolescents, and Adults with Refractory/Resistant Ewing Sarcoma CHICAGO and FORT WORTH, Texas, July 17, 2025 (GLOBE NEWSWIRE) ...

A phase 2a trial shows tigilanol tiglate achieves an 80% response rate in soft tissue sarcoma, offering hope for effective treatment options. Findings from the QB46C-H07 phase 2a clinical trial ...

Brian Andrew Van Tine, MD, PhD, discusses positive results from Moleculin's Annamycin trial for Soft Tissue Sarcoma Lung Metastases. Moleculin Biotech, Inc. has announced positive topline results from ...

Responders (Stable Disease or Partial Response) after 2 cycles of Annamycin showed improvement in OS and Progression Free Survival (“PFS”) Clinical Benefit Rate (“CBR”) was 59.4% (n=32), comprised of ...

A study conducted by researchers from the Agency for Science, Technology and Research (A*STAR), National Cancer Centre Singapore (NCCS) and National University of Singapore (NUS), in collaboration ...

Introduction: Canine soft tissue sarcomas (STSs) are locally aggressive mesenchymal tumors with variable recurrence rates, and often, their therapy is limited to surgical excision. CD117 (KIT) is a ...